Janjigian, Y. Y., Park, B. J., Zakowski, M. F., Ladanyi, M., Pao, W., D’Angelo, S. P., . . . Azzoli, C. G. (2011). Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations.
Čikaški stil citiranjaJanjigian, Yelena Y., et al. Impact On Disease-free Survival of Adjuvant Erlotinib or Gefitinib in Patients With Resected Lung Adenocarcinomas That Harbor Epidermal Growth Factor Receptor (EGFR) Mutations. 2011.
MLA način citiranjaJanjigian, Yelena Y., et al. Impact On Disease-free Survival of Adjuvant Erlotinib or Gefitinib in Patients With Resected Lung Adenocarcinomas That Harbor Epidermal Growth Factor Receptor (EGFR) Mutations. 2011.